Figure 3

G28UCM plus trastuzumab, lapatinib and erlotinib blocked the activation of HER2, AKT or ERK1/2 proteins. AU565 cells were treated with G28UCM (30 μM) plus trastuzumab (1 μM), lapatinib (5 μM), erlotinib (8 μM) or cetuximab (15 μg/ml) for 12, 24, and 48 h, and equal amounts of lysates were immunoblotted with anti-FASN, anti-HER2, anti- AKT, and anti-ERK1/2 antibodies. Activation of the protein under study was analysed by assessing the phosphorylation status using the corresponding phospho-specific antibody. Blots were reprobed for β-actin as loading control. Gels shown are representative of those obtained from two or three independent experiments.